Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
NCT06257693
This study is recruiting at 10 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Adenocarcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 21 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Alessa Therapeutics Inc.
- Last updated on ClinicalTrials.gov
- August 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Urology Associates of Central California · Fresno, CA
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center · San Francisco, CA
Illinois · 1
- Northwestern University · Chicago, IL
Louisiana · 1
- Mary Bird Cancer Center · Metairie, LA
Maryland · 2
- Johns Hopkins University School of Medicine · Baltimore, MD
- National Institutes of Health Clinical Center · Bethesda, MD
Oregon · 1
- VA Portland Health Care System · Portland, OR
South Carolina · 1
- Atlantic Urology Specialists · Myrtle Beach, SC
Virginia · 1
- Virginia Commonwealth University · Richmond, VA
Wisconsin · 1
- Aurora Urology · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.